Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 12.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 129,430 shares of the company's stock after selling 18,708 shares during the quarter. QRG Capital Management Inc.'s holdings in Teva Pharmaceutical Industries were worth $1,989,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Teva Pharmaceutical Industries by 30.7% during the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after buying an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares during the last quarter. Ion Asset Management Ltd. grew its stake in Teva Pharmaceutical Industries by 1.1% during the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company's stock valued at $807,766,000 after acquiring an additional 409,778 shares in the last quarter. Lingotto Investment Management LLP grew its stake in Teva Pharmaceutical Industries by 2.6% during the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after acquiring an additional 688,862 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Teva Pharmaceutical Industries by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock valued at $203,642,000 after acquiring an additional 489,041 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president now directly owns 9,989 shares in the company, valued at $170,012.78. This represents a 38.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Trading Down 0.5%

NYSE TEVA traded down $0.09 during trading hours on Friday, reaching $16.97. The company had a trading volume of 10,762,752 shares, compared to its average volume of 10,239,416. The stock has a 50-day moving average of $16.32 and a 200 day moving average of $17.42. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The stock has a market capitalization of $19.46 billion, a P/E ratio of -14.75, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the previous year, the company earned $0.48 earnings per share. The firm's quarterly revenue was up 1.9% compared to the same quarter last year. As a group, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TEVA has been the topic of several recent research reports. The Goldman Sachs Group started coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 target price on the stock. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price for the company. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $24.44.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.